Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks
May 2024- In Eli Lilly and Company's pivotal Phase 3 VIVID-1 study,…
FDA Approves Eli Lilly’s Zepbound™ for Obesity Treatment
INDIANAPOLIS: Eli Lilly and Company's (NYSE: LLY) innovative obesity treatment, Zepbound™ (tirzepatide)…